Markets & Investors
Markets & Investors
Atriva Therapeutics approaches the future
Atriva is a privately held company.
Investors include:
- Meneldor, an investment fund focused on early stage biotech and pharma companies that (re)develop (New) Biological or Chemical Molecular Entities, that have outstanding technology with strong IP, address significant unmet medical needs and attractive markets.
- High-Tech Gründerfonds (HTGF), a Germany-based seed investor for innovative technologies and business models, successful in supporting the best founders whose ideas can revolutionize entire industries and improve people’s lives.
- Private investors, Atriva management and founders.
- The European Investment Bank has financed the company with a Venture Loan of up to €24m under the Infectious Diseases Finance Facility as part of Horizon 2020, the EU research and innovation programme.
- The German Government has granted the company an R&D subsidy of €11.3m in 2021.
Business Development
Out-licensing
Atriva focuses on drug development up to clinical validation.
We are interested in partnering with pharmaceutical companies who have successful marketing and sales capabilities on an international level.
In-licensing
We welcome new development partnerships and collaborations with both industry and academia.
